Vinblastine
- Generic Name
- Vinblastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H58N4O9
- CAS Number
- 865-21-4
- Unique Ingredient Identifier
- 5V9KLZ54CY
- Background
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
- Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
- Associated Conditions
- Advanced Soft Tissue Sarcoma, Autoimmune Hemolytic Anemia, Bladder Cancer, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Letterer-Siwe disease, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Advanced Alibert-Bazin syndrome, Advanced Testicular cancer, Histiocytic lymphoma, Refractory Breast cancer
- Associated Therapies
- -
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 521
- Registration Number
- NCT00005047
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States
🇺🇸William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00002882
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00001570
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00038558
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.